Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths, and mistakes.

Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths, and mistakes. Br J Radiol. 2018 Jan 05;:20170915 Authors: Wardman P Abstract Nitroimidazoles have been extensively explored as hypoxic cell radiosensitizers but have had limited clinical success, with efficacy restricted by toxicity. However, they have proven clinically useful as probes for tumour hypoxia. Both applications, and probably much of the dose-limiting toxicities, reflect the dominant chemical property of electron affinity or ease of reduction, associated with the nitro substituent in an aromatic structure. This single dominant property affords unusual, indeed extraordinary flexibility in drug or probe design, suggesting further development is possible in spite of earlier limitations, in particular building on the benefit of hindsight and an appreciation of errors made in earlier studies. The most notable errors were: the delay in viewing cellular thiol depletion as a likely common artefact in testing in vitro; slow recognition of pH-driven concentration gradients when compounds were weak acids and bases; and a failure to explore the possible involvement of pH and ascorbate in influencing hypoxia probe binding. The experience points to the need to involve a wider range of expertise than that historically involved in many laboratories when studying the effects of chemicals on radiation response or using diagnostic probes. PMID:...
Source: The British Journal of Radiology - Category: Radiology Authors: Tags: Br J Radiol Source Type: research